Metronidazole 0.75/1% gel — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Rosacea

• Azelaic Acid
• Doxycycline
• Ivermectin

What Metronidazole 0.75/1% gel is approved for (FDA label)

Metronidazole Gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. Metronidazole Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: October 31, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metronidazole 0.75/1% gel (FDA label)

Gel, 1%. Metronidazole Gel is a clear, colorless to pale yellow gel. Each gram of Metronidazole Gel contains 10 mg (1%) of metronidazole. Gel,1%

Source: FDA prescribing information (DailyMed). Set ID: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a. SPL document ID: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b. Label effective date: October 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metronidazole 0.75/1% gel (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Neurologic Disease [see Warnings and Precautions (5.1)] Contact Dermatitis [see Warnings and Precautions (5.3)] Eye Irritation [see Warnings and Precautions (5.4)] Most common adverse reactions (incidence > 2%) are nasopharyngitis, upper respiratory tract infection, and headache. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma, at 1-844-825-8500, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a. SPL document ID: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b. Label effective date: October 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metronidazole 0.75/1% gel (FDA label)

Metronidazole Gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. Metronidazole Gel is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a. SPL document ID: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b. Label effective date: October 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metronidazole 0.75/1% gel (FDA label)

Neurologic Disease: Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. Immediately reevaluate Metronidazole Gel if abnormal neurologic signs appear. ( 5.1 ) Blood Dyscrasias: Metronidazole Gel is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia. ( 5.2 ) Contact Dermatitis: If dermatitis occurs, patients may need to discontinue use. ( 5.3 ) Eye Irritation: Topical metronidazole has been reported to cause tearing of the eyes. Avoid contact with the eyes. ( 5.4 ) 5.1 Neurologic Disease Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. Immediately reevaluate Metronidazole Gel therapy if abnormal neurologic signs appear.

Source: FDA prescribing information (DailyMed). Set ID: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a. SPL document ID: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b. Label effective date: October 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metronidazole 0.75/1% gel (FDA label)

Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when prescribing for patients who are receiving anticoagulant treatment. Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when administering Metronidazole Gel concomitantly to patients who are receiving anticoagulant treatment. ( 7 )

Source: FDA prescribing information (DailyMed). Set ID: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a. SPL document ID: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b. Label effective date: October 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.